The unpredictable erythrocyte deformability alteration in some hematological disorders: How the classification of primary hyperviscosity syndromes could change
Restricted accessResearch articleFirst published online May 17, 2023
The unpredictable erythrocyte deformability alteration in some hematological disorders: How the classification of primary hyperviscosity syndromes could change
According to Wells classification, it is possible to distinguish the primary hyperviscosity syndromes in polycythemic, sclerocythemic and sieric and/or plasmatic. In polycythemia vera, multiple myeloma, Waldenström’s macroglobulinemia, and monoclonal gammopathy of undetermined significance, we have observed an unexpected behaviour of the erythrocyte deformability. This data highlights that the hemorheological alteration present in polycythemia vera has not been related to the increase of RBC mass only, as well as that present in plasmacellular dyscrasias has not been attributable to the increase of plasma viscosity only.
The aim of this paper is to suggest some starting points for an accurate reflection, emphasizing the need of a revision of the current classification of primary hyperviscosity syndromes.
CopleyAL. Introduction: On theway to modern clinical hemorheology. Clinical Hemorheology Eds Chien S, Dormandy J, Ernst E, Matrai A. Dordrecht: Martinus Nijhoff Publishers; 1987, pp. 1–8.
2.
WellsR. Syndromes of hyperviscosity. N Engl J Med. 1970;283(4):183–6. DOI: 10.1056/NEJM197007232830406.
3.
DormandyJA. Clinical significance of blood viscosity. Ann R Coll Surg Engl. 1970;47(4):211–28.
4.
DormandyJA. Influence of blood viscosity on blood flow and the effect of low molecular weight dextran. Br Med J. 1971;4(5789):4716–9. DOI: 10.1136/bmj.4.5789.716.
5.
ForconiS, WildP, MunzelT and GoriT. Endothelium and hyperviscosity. Clin Hemorheol Microcirc. 2011;49(1-4):487–91. DOI: 10.3233/CH-2011-1498.
6.
ForconiS and GoriT. Endothelium and hemorheology. Clin Hemorheol Microcirc. 2013;53(1-2):3–10. DOI: 10.3233/CH-2012-1571.
7.
CabralesP and TsaiAG. Plasma viscosity regulates systemic and microvascular perfusion during acute extreme anemic conditions. Am J Physiol Heart Circ Physiol. 2006;291(5):H2445–52. DOI: 10.1152/ajpheart.00394.2006.
8.
Salazar VázquezBY, MartiniJ, Chávez NegreteA, CabralesP, TsaiAG and IntagliettaM. Microvascular benefits of increasing plasma viscosity and maintaining blood viscosity: Counterintuitive experimental findings. Biorheology. 2009;46(3):167–79. DOI: 10.3233/BIR-2009-0539.
9.
GaehtgensP, PriesAR and LeyK. Structural, hemodynamic, and rheological characteristics of blood flow in the circulation. Clinical Hemorheology Eds Chien S, Dormandy J, Ernst E and Matrai A. Dordrect: Martinus Nijhoff Publishers; 1987, pp. 97–124.
10.
LipowskyHH. Blood rheology aspects of the microcirculation. In Handbook of Hemorheology and Hemodynamics Eds Baskurt OK, Hardman MR, Rampling MW, Meiselman HJ, Amsterdam: Ios Pres; 2007, pp. 307–321.
11.
RuefP, et al. The Shear Stress Diffractometer Rheodyn SSD for Determination of Erythrocyte Deformability II. Sensitivity to Detect Abnormal Erythrocyte Deformability. 1996, pp. 749-752.
12.
Schmid-SchönbeinH, RuefP and LinderkampO. The Shear Stress Diffractometer Rheodyn SSD for Determination of Erythrocyte Deformability I. Principles of Operation and Reproducibility. 1996, pp. 745-748.
13.
HardemanMR, GoedhartPT and ShinS. Methods in Hemorheology. Handbook of Hemorheology and Hemodynamics. Baskurt OK, et al. (Eds.). IOS Press; 2007.
14.
StreichmanS, AvdiN, JoffeG, MatathiasL and TatarskyI. Some characteristics of circulating erythrocytes in polycythaemia vera: Common features with normal young and foetal red blood cells. Scand J Haematol. 1986;36(1):33–8. DOI: 10.1111/j.1600-0609.1986.tb02646.x.
15.
ArnaudJ, PrisJ, BrunH and ConstansJ. Consequences of moderate hypoxia on red cell glycolytic metabolism in polycythemia rubra vera. Ann Biol Clin (Paris). 1991;49(1):9–13.
16.
FujitaH, SakumaR, TomiyamaJ, HamakiT, OhwadaA, KurosawaS and NishimuraS. Increased phosphatidylserine exposure on the erythrocyte membrane in patients with polycythaemia vera. Br J Haematol. 2011;152(2):238–40. DOI: 10.1111/j.1365-2141.2010.08379.x.
17.
WautierMP, HéronE, PicotJ, ColinY, HermineO and WautierJL. Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion. J Thromb Haemost. 2011;9(5):1049–55. DOI: 10.1111/j.1538-7836.2011.04251.x.
18.
HoffmanR, PapayannopoulouT, LandawS, WassermanLR, DeMarshQB, ChenP and StamatoyannopoulosG. Fetal hemoglobin in polycythemia vera: Cellular distribution in 50 unselected patients. Blood. 1979;53(6):1148–55.
19.
StreichmanS, SegalE, TatarskyI and MarmurA. Moving boundary electrophoresis and sialic acid content of normal and polycythaemic red blood cells. Br J Haematol. 1981;48(2):273–9. DOI: 10.1111/j.1365-2141.1981.tb08460.x.
20.
BratosinD, PaliiC, MoiceanAD, ZanettaJP and MontreuilJ. Reduced diversity of the human erythrocyte membrane sialic acids in polycythemia vera. Absence of N-glycolylneuraminic acid and characterisation of N-acetylneuraminic acid 1,7 lactone. Biochimie. 2007;89(3):355–9. DOI: 10.1016/j.biochi.2006.11.004.
21.
BrussonM, De GrandisM, CochetS, BigotS, MarinM, LeducM, GuillonneauF, MayeuxP, PeyrardT, ChomienneC, Le Van KimC, CassinatB, KiladjianJJ and El NemerW. Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera. Haematologica. 2018;103(6):972–81. DOI: 10.3324/haematol.2017.182303.
22.
DabrowskiZ, DybowiczAJ, MarchewkaA, TeległówA, SkotnickiA, ZduńczykA, AleksanderP and Filar-MierzwaK. Elongation index of erythrocytes, study of activity of chosen erythrocyte enzymes, and the levels of glutathione, malonyldialdehyde in polycythemia vera (PV). Clin Hemorheol Microcirc. 2011;47(3):169–76. DOI: 10.3233/CH-2010-1368.
23.
TanashyanM, ShabalinaA and RoitmanE. Microrheological disorders in patients with polycythemia vera suffered acute ischemic stroke. Mol Cell Biochem. 2022;477(4):989–94. DOI: 10.1007/s11010-021-04352-6.
24.
LoPresti R, CaraccioloC, MontanaM, BaroneR, CataniaA and CaimiG. Erythrocyte deformability evaluated by laser diffractometry in polycythemia vera. Clin Hemorheol Microcirc. 2012;50(3):189–92. DOI: 10.3233/CH-2010-1422.
25.
CaimiG, CarlisiM, MontanaM, GallàE, HoppsE, Lo PrestiR and SiragusaS. Red blood cell deformability in multiple myeloma1. Clin Hemorheol Microcirc. 2018;69(1-2):233–8. DOI: 10.3233/CH-189121.
NakamuraMT and NaraTY. Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr. 2004;24:345–76. DOI: 10.1146/annurev.nutr.24.121803.063211.
29.
RzehakP, HeinrichJ, KloppN, SchaefferL, HoffS, WolframG, IlligT and LinseisenJ. Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes. Br J Nutr. 2009;101(1):20–6. DOI: 10.1017/S0007114508992564.
30.
GuoL, TongD, YuM, ZhangY, LiT, WangC, ZhouP, JinJ, LiB, LiuY, LiuR, NovakovicVA, DongZ, TianY, KouJ, BiY, ZhouJ and ShiJ. Phosphatidylserine-exposing cells contribute to the hypercoagulable state in patients with multiple myeloma. Int J Oncol. 2018 Jun;52(6):1981–90. DOI: 10.3892/ijo.2018.4354.
31.
VuckovicS, VandykeK, RickardsDA, McCauley WinterP, BrownSHJ, MitchellTW, LiuJ, LuJ, AskenasePW, YurievE, CapuanoB, RamslandPA, HillGR, ZannettinoACW and HutchinsonAT. The cationic smallmolecule GWis cytotoxic to high phosphatidylserine-expressingmyeloma cells. Br J Haematol. 2017;177(3):423–40. DOI: 10.1111/bjh.14561.
32.
OrbachA, ZeligO, YedgarS and BarshteinG. Biophysical and biochemical markers of red blood cell fragility. Transfus Med Hemother. 2017;44(3):183–7. DOI: 10.1159/000452106.
33.
ZhangY, ZhangW, WangS, WangC, XieJ, ChenX, XuY and MaoP. Detection of erythrocytes in patients with multiple myeloma using atomic force microscopy. Scanning. 2012;34(5):295–301. DOI: 10.1002/sca.21008.
34.
LiuJ and LiJ. Detection of erythrocytes in patients with Waldenstrom macroglobulinemia using atomic force microscopy. Acta Biochim Biophys Sin (Shanghai). 2014;46(5):420–5. DOI: 10.1093/abbs/gmu015.
35.
CastilloJJ. Plasma cell disorders. Prim Care. 2016;43(4):677–91. DOI: 10.1016/j.pop.2016.07.002.
36.
Perez RogersA and EstesM. Hyperviscosity Syndrome. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2022. 2021.
37.
RamakrishnanS, GrebeR, SinghM and Schmid-SchönbeinH. Haemorheological behaviour of erythrocytes & risk factor profile in patients suffering from Waldenström’s macroglobulinaemia. Indian J Med Res. 1998;107:128–33.
38.
RamakrishnanS, DegenhardtR and VietzkeK. Erythrocyte deformability in Waldenström’s macroglobulinemia. Clin Hemorheol Microcirc. 2000;22(1):17–20.
39.
CaimiG, CarlisiM, UrsoC, Lo PrestiR and HoppsE. Clinical disorders responsible for plasma hyperviscosity and skin complications. Eur J Intern Med. 2017;42:24–8. DOI: 10.1016/j.ejim.2017.04.001.
40.
VieraS, LudekP, ZdenekA, MartaK, MartinŠ, SabinaŠ and ZdenekK. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS). Klin Onkol. 2018;31(4):270–6. English. DOI: 10.14735/amko2018270.
41.
López GómezJM, Sacristán EncisoB, Fernández-Cavada PolloMJ, Bueno GarcíaV and Gómez VeraS. Gammapatía monoclonal de significado incierto y evolución a mieloma múltiple: Experiencia en 153 pacientes [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients]. Semergen.. Spanish. 2021;47(7):441–7. DOI: 10.1016/j.semerg.2021.05.011.
42.
KangKW, SongJE, LeeBH, JeonMJ, YuES, KimDS, LeeSR, SungHJ, ChoiCW, ParkY and KimBS. A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea. Sci Rep. 2021;11(1):18449. DOI: 10.1038/s41598-021-97664-y.
43.
CaimiG, HoppsE, CarlisiM, MontanaM, GallàE, Lo PrestiR and SiragusaS. Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS). Clin Hemorheol Microcirc. 2018;68(1):51–9. DOI: 10.3233/CH-170289.
44.
MeletisJ, TerposE, SamarkosM, MeletisC, ApostolidouE, KomninakaV, KorovesisK, AnargyrouK, BenopoulouO, MavrogianniD, VariamiE, ViniouN and KonstantopoulosK. Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias. Int J Hematol. 2002;75(1):40–4. DOI: 10.1007/BF02981977.
45.
CarlisiM, MancusoS, Lo PrestiR, La MannaMP, OrlandoV, SiragusaS and CaimiG. Erythrocyte deformability in a group of monoclonal gammopathy of undetermined significance (MGUS) subjects. Preliminary analysis. Series in Biomechanics. 2021;35:45–50.
46.
KristinssonSY, PfeifferRM, BjörkholmM, GoldinLR, SchulmanS, BlimarkC, MellqvistUH, WahlinA, TuressonI and LandgrenO. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: A population-based study. Blood. 2010;115(24):4991–8. DOI: 10.1182/blood-2009-11-252072.
47.
GregersenH, NørgaardM, SeverinsenMT, EngebjergMC, JensenP and SørensenHT. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol. 2011;86(2):129–34. DOI: 10.1111/j.1600-0609.2010.01539.x.
48.
van de DonkNW, PalumboA, JohnsenHE, EngelhardtM, GayF, GregersenH, HajekR, KleberM, LudwigH, MorganG, MustoP, PlesnerT, SezerO, TerposE, WaageA, ZweegmanS, EinseleH, SonneveldP and LokhorstHM; European Myeloma Network. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: Recommendations from the European Myeloma Network. Haematologica. 2014;99(6):984–96. DOI: 10.3324/haematol.2013.100552.
49.
VayáA and SuescunM. Hemorheological parameters as independent predictors of venous thromboembolism. Clin Hemorheol Microcirc. 2013;53(1-2):131–41. DOI: 10.3233/CH-2012-1581.
50.
DaiX, WangX, HuangZ, WangK and DingW. Exact association between preoperative blood viscosity and postoperative deep venous thrombosis risk in knee osteoarthritis patients: A 10-year retrospective study. Clin Appl Thromb Hemost. 2021;27:10760296211048896. DOI: 10.1177/10760296211048896.
51.
O’SullivanLR, Meade-MurphyG, GilliganOM, MykytivV, YoungPW and CahillMR. Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. Br J Haematol. 2021;192(2):322–32. DOI: 10.1111/bjh.16774.
52.
CrowleyMP, KevaneB, O’SheaSI, QuinnS, EganK, GilliganOM and Ní ÁinleF. Plasma thrombin generation and sensitivity to activated protein C among patients with myeloma and monoclonal gammopathy of undetermined significance. Clin Appl Thromb Hemost. 2016;22(6):554–62. DOI: 10.1177/1076029615625825.
53.
BaskurtOK. Mechanisms of blood rheology alterations. In: Baskurt OK, Hardeman MR, Rampling MW, Meiselman HJ. eds Handbook of Hemorheology and Hemodynamics. Amsterdam: IOS Press; 2007, pp. 170–90.
54.
DumasG, MerceronS, ZafraniL, CanetE, LemialeV, KouatchetA and AzoulayE. Syndrome d’hyperviscosité plasmatique [Hyperviscosity syndrome]. Rev Med Interne. 2015;36(9):588–95. French. DOI: 10.1016/j.revmed.2015.02.005.
55.
SloopGD. A classification of disorsers of blood viscosity by pathologic mechanism. In Blood Viscosity. Its role in cardovascular pathophysiology and hematology. New York: Sloop GD Editor - Nova Science Publishers, Inc; 2017, pp. 83–106.
